Buprenorphine appears to have a ceiling effect on respiratory depression, but not analgesia in healthy young patients. However, the efficacy and side-effects of buprenorphine in the setting of acute pain are poorly characterized. The aim of this study was to characterize the analgesic efficacy and adverse effects of buprenorphine compared with morphine in the acute pain setting. A systematic review of five databases was performed. Randomised controlled trials (RCTs) comparing buprenorphine with morphine in acute pain management were included. Studies performed outside of the hospital setting were excluded. The a priori primary outcomes included pain, respiratory depression, and sedation. Secondary outcomes included requirement for rescue analgesia, time to rescue analgesia, nausea, vomiting, dizziness, hypotension, and pruritus. Twenty-eight RCTs with 2210 patients met the inclusion criteria. There was no difference in pain [visual analogue scale weighted mean difference (WMD)¼À0.29; 95% confidence interval (CI)¼À0.62 to 0.03; I 2 ¼99%; P¼0.07], incidence of respiratory depression [odds ratio (OR)¼2.07; 95% CI¼0.78e5.51; I 2 ¼30%; P¼0.14], or sedation (OR¼1.44; 95% CI¼0.76e2.74; I 2 ¼23%; P¼0.26). There was only one secondary outcome with an overall significant difference; buprenorphine use was associated with significantly less pruritus (OR¼0.31; 95% CI¼0.12e0.84; I 2 ¼6%; P¼0.02).
Effective pain management in the early postoperative period is associated with higher levels of patient satisfaction, earlier mobilization, and reduced length of hospital stay. 1 One of the mainstays of early postoperative pain management is the use of i.v. and oral opioids. 2 Use of these agents is not without risk, commonly resulting in adverse effects such as sedation, hypotension, nausea, vomiting, and respiratory depression. 2 Buprenorphine is an opioid that is growing in popularity in the acute pain setting. 2 The main reason for its rising popularity is its full-agonist analgesic and partial-agonist respiratory depression properties. 2 Current research and guidelines
state that buprenorphine appears to have a ceiling effect for respiratory depression and not for analgesia. 2e4 Interestingly, these guidelines generally only reference two pharmacokinetic studies, one in rats 3 and the other in healthy 22e35-yrold patients weighing 62e92 kg. 4 Therefore, the clinical utility of the recommendations drawn from these studies is questionable. 5 The aim of this study is to characterize the analgesic efficacy and adverse effects of buprenorphine when used for acute pain management in the hospital setting. We assessed the clinical effect of buprenorphine by performing a systematic review and metaanalysis of randomised controlled trials (RCTs) comparing buprenorphine with morphine.
Methods

Search strategy
Five databases (Cochrane trials registry, SCOPUS, Medline, CINAHL, and Web of Science) were systematically searched from the inception of the databases until May 2017. This search was conducted by two independent reviewers (L.W. and A.H.) searching the terms: (i) 'buprenorphine' AND 'acute pain'; (ii) 'buprenorphine' AND 'post-operative pain'; (iii) 'buprenorphine' AND 'surgical pain'. A manual reference check and citation check of included papers was performed to identify any additional studies.
Study eligibility
For a study to be included, the authors were required to report on the use of buprenorphine vs morphine in the management of acute pain in the hospital setting. Only RCTs were eligible for inclusion and there were no language criteria for exclusion. Two reviewers (L.W. and A.H.) independently assessed and agreed upon each study for inclusion in this systematic review.
Morphine was chosen as a 'treatment-as-usual' control group, given the majority of in-hospital acute pain studies are conducted with an active treatment control and morphine is a well-studied and understood opioid. This maximizes the external validity of this review, keeping our comparisons inline with clinical decisions that face clinicians. Studies investigating the use of buprenorphine in the setting of chronic pain or opioid substitution were excluded.
Data extraction
Two reviewers (L.W. and A.H.) independently extracted data from each article that met the inclusion criteria. The data extracted from each study included the study design, patient characteristics, and clinical outcome results. The data collected by each reviewer were then compared for homogeneity.
Clinical outcome measures
Our a priori primary outcomes of interest were analgesic effect [as measured by visual analogue scale (VAS)], respiratory depression, and sedation. The secondary outcomes we defined were requirement for rescue analgesia, time to rescue analgesia, nausea, vomiting, dizziness, hypotension, and pruritus.
Level of evidence, risk of bias, and outcome level of evidence ranking Each article was evaluated using the Centre for Evidence Based Medicine: Levels of Evidence Introduction Document. 6 These studies were then assessed for risk of bias and methodological quality using the Cochrane Collaboration's tool for assessing the risk of bias. 7 The results from each study were then grouped into individual outcomes. As a result of the anticipated inconsistencies in outcome reporting measures, both qualitative and quantitative analyses were performed. The qualitative analysis was conducted by grouping outcomes and then assigning a level of evidence ranking based on the collective strength of evidence.
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(i) Strong evidence: two or more high-quality (quality score !4) randomised RCTs with !75% consistency in findings (ii) Moderate evidence: one high-quality RCT and two or more low-quality studies with !75% consistency in findings (iii) Limited evidence: one high-quality RCT or multiple lowquality studies with !75% consistency in findings (iv) Conflicting evidence: multiple low, high-quality studies, or both with 75% consistency in findings (v) No evidence: no studies could be found, may include technique reports
Statistical analyses
The combined data were analysed using RevMan 5.3 software (The Nordic Cochrane Centre, Copenhagen, Denmark), using the odds ratio (OR) with 95% confidence interval (CI) for dichotomous outcomes, and the weighted mean difference (WMD) with 95% CI for continuous outcomes. The ManteleHaenszel random effects model was used. Heterogeneity was assess using the I 2 statistic, with an I 2 >50% indicating significant heterogeneity. A P-value of <0.05 provided evidence of significant relative risk (RR) and WMD. A P-value of <0.10 was used to demonstrate heterogeneity of intervention effects. A sensitivity analysis was performed on each outcome by separating the adult and paediatric studies.
Reporting
This study was reported in line with Preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. 9 
Results
Literature search results
The initial systematic literature search yielded 2340 citations and a further 15 citations were identified through a manual citation and reference search of relevant articles (Fig. 1) . After the removal of duplicates, animal studies, and non-clinical studies, 340 citations remained. Of these, 88 abstracts were screened and 54 full texts were retrieved for review. Twentyeight articles met the inclusion criteria (Fig. 1) . These 28 studies included 2210 patients. All studies investigated the management of acute pain in the hospital setting, comparing buprenorphine with morphine (Table 1) . Each study was then screened for risk of bias and methodological quality using the Cochrane Collaboration's tool for assessing the risk of bias (Fig. 2) . Fifteen studies met the criteria for high-quality RCTs, leaving 13 low-quality RCTs.
Primary outcomes
Pain
Pain was assessed via a variety of pain scales and at numerous different time points. Qualitative analysis was performed using all pain rating scales based on whether there was a significant difference between morphine and buprenorphine groups. Quantitative analysis was performed on VAS scores and other linear pain scales that could be converted into a VAS score. These data were analysed in four time-groupings: less than 1 h, 1e7 h, 8e23 h, and 24e48 h. and four showed buprenorphine to be significantly better.
Only one study used VAS score (WMD¼À4.10; 95% CI¼À4.82 to À3.38; P<0.00001). Six studies measured pain at 24e48 h. Three showed no difference and three showed buprenorphine to be significantly better. The overall result of all time points combined was no difference between morphine and buprenorphine (WMD¼À0.29; 95% CI¼À0.62 to 0.03; I 2 ¼99%; P¼0.07;
Supplementary material Fig. S1 ). There were no paediatric studies included in the quantitative analysis of pain.
Respiratory depression
Overall, 19 studies reported on respiratory depression via several outcome measures. 10e14,16,18e20,22,24e29,31,33,35,37 Of these, 12 were high-quality and seven were low-quality. On qualitative analysis there was conflicting evidence. Fourteen of these showed no significant difference. Four showed significantly greater respiratory depression with buprenorphine and one showed significantly greater respiratory depression with morphine. Quantitative analysis was performed on 10 studies measuring the incidence of respiratory depression (respiratory rate <8e12 bpm) showing no difference (OR¼2.07; 95% CI 0.78e5.51; P¼0.14), without significant heterogeneity (I 2 ¼30%; P¼0.20) (Fig. 3 ). There was only one paediatric study in the quantitative analysis. 25 Sensitivity analysis of the adult studies remained largely unchanged (OR¼1.92; 95% CI¼0.65e5.66; I 2 ¼37%; P¼0.24). Six showed no difference and the other five showed significantly more sedation with buprenorphine. This was also reflected on quantitative analysis of studies measuring the incidence of sedation (Fig. 4) 
Secondary outcomes
Rescue analgesia
Five high-quality and one low-quality study measured the need for rescue analgesia after the buprenorphine or morphine administration. 19, 20, 24, 28, 31, 35 These studies showed high level evidence that there is no difference in the incidence of breakthrough analgesia (OR¼0.67; 95% CI¼0.28e1.61; I 2 ¼53%; P¼0.37; Fig. S2 ). One paediatric study was included in the quantitative analysis of rescue analgesia requirement. 25 There was no change in significant difference in breakthrough analgesia requirement in the adult population (OR¼0.70; 95% CI¼0.30e1.52; I 2 ¼58%; P¼0.37).
Time to rescue analgesia
Four high-quality and two low-quality studies measured time to breakthrough analgesia. There is high level evidence to support no difference between buprenorphine on qualitative analysis. 20 
Nausea
Twenty-one studies (13 low-quality and eight high-quality) reported on nausea with high level evidence showing no difference between buprenorphine and morphine. 10,11,13e16,19,20,22e28,31e37 This was reflected in the quantitative analysis of the incidence of nausea (OR¼1.05; 95% CI¼0.77e1.44; I 2 ¼0%; P¼0.76; Fig. S4 ). Two paediatric studies were included in the sensitivity analysis. 20, 25 The incidence of nausea remained mostly unchanged (OR¼0.99; 95% CI¼0.71e1.38; I 2 ¼0%; P¼0.94).
Vomiting
Thirteen studies (eight high-quality and five low-quality) reported on the incidence of vomiting.
These showed high level evidence that there is no significant difference. This was shown in the quantitative analysis of the incidence of vomiting (OR¼1.14; 95% CI¼0.73e1.78; I 2 ¼7%; P¼0.57; Fig. S5 ). No paediatric studies measured the incidence of vomiting.
Dizziness
Eight studies surveyed patients on the sensation of dizziness showing high level evidence that there is no difference between agents. 10, 11, 14, 19, 22, 25, 27, 31 This was further demonstrated on the quantitative analysis of incidence of dizziness (OR¼1.41; 95% CI¼0.67e3.00; I 2 ¼20%; P¼0.37; Fig. S6 ). One paediatric study measured the incidence of dizziness. In the adult population there was no significant difference with either analgesic agent (OR¼1.29; 95% CI¼0.59e2.86; I 2 ¼24%;
P¼0.52).
Hypotension
High-quality evidence for no difference in the incidence of hypotension was demonstrated by five high-quality and five low-quality studies. 12,18e20,22,30e34 This was again shown in the quantitative analysis of incidence of hypotension (OR¼0.41; 95% CI¼0.11e1.58; I 2 ¼48%; P¼0.20; Fig. S7 ). No paediatric studies measured the incidence of hypotension.
Pruritus
Three low-quality and three high-quality studies measured the incidence of pruritus. 11, 26, 27, 31, 32, 34 High level evidence showed significantly less incidence of pruritus with buprenorphine (OR¼0.31; 95% CI¼0.12e0.84; I 2 ¼6%; P¼0.02; Fig. S8 ).
Only one paediatric study measured the incidence of pruritus.
In the adult studies, the incidence of pruritus remained significantly lower with buprenorphine (OR¼0.25; 95% CI¼0.09e0.66; I 2 ¼ 0%; P¼0.005).
Discussion
This is the first systematic review to characterize the effect of buprenorphine in the management of acute pain. This study combined the results of 28 RCTs comparing buprenorphine with morphine. This study included 2210 patients and consisted of 24 adult studies, three paediatric studies, and one combined study. This review included only RCTs comparing buprenorphine with morphine and reports on the analgesic efficacy of these two agents and their side-effects. Only in recent years has it been known that buprenorphine has no ceiling effect on analgesia, making it a useful agent in the management of acute pain. 4 Our study confirms this, showing no difference in the analgesia provided by buprenorphine compared with morphine. The analgesia provided by buprenorphine compared with morphine was comparable from less than 1 h through to 48 h after operation. In addition to this, buprenorphine administered in the emergency department setting was reported in four studies and was, once again, equivalent to morphine for the treatment of acute pain. 21, 22, 31, 37 These findings may seem surprising considering the pharmacology of buprenorphine, a mixed agonist-antagonist which is approximately 33 times more potent than morphine but has a lower intrinsic activity. 2, 38 Buprenorphine has a higher affinity for mu-opioid receptors compared with morphine (50Â greater) and its effects last much longer (halflife of 166 min). 34 After i.m. administration, onset of effect is slow and occurs in about 30 min whilst duration of action is at least 8e10 h. Buprenorphine is slow to dissociate from opioid receptors, which accounts for its long duration of action and resistance to antagonism with naloxone. The antagonist effects of buprenorphine reflect the ability of this drug to displace opioid agonists from mu receptors. 38 Unlike other opioid agonists-antagonists, dysphoria is unlikely to occur in association with this drug. Despite its slower onset of action, buprenorphine was found to be just as effective as morphine within the first hour of treatment with respect to analgesia. This was demonstrated in studies that assessed patients in the emergency department after injury and in the post-anaesthetic care unit immediately after operation. In addition to this, buprenorphine was also found to be equivalent to morphine when assessing the need for breakthrough analgesia. Studies which assessed the delivery of buprenorphine via patient-controlled analgesia devices could quantify the cumulative volumes of buprenorphine and morphine in equipotent doses required to achieve adequate analgesia. Chang and colleagues 11 found that larger volumes were required in the buprenorphine arm in the early postoperative period (0e6 h), but this was not the case in the following 24e48 h. This finding is consistent with buprenorphine's slower onset and longer duration of action when compared with morphine. In all other studies, equivalent dosing regimens were used. Perhaps less surprising when considering buprenorphine's pharmacological profile is the time to breakthrough analgesia, which was also found to be equivalent to morphine overall. In the paediatric population, however, the buprenorphine group had an increased time to rescue analgesia of 114 min longer than the morphine group. Buprenorphine remains avidly bound to mu-receptors for an extended period of time and thus maintains adequate analgesia for 8e10 h after sublingual administration.
The purpose of this review was to address the lack of evidence with respect to the effect of buprenorphine on respiratory depression. Significantly, in this review there was no difference in respiratory depression or sedation when compared with morphine. This challenges the commonlymade assertion that buprenorphine has a ceiling effect on respiratory depression 38 and is thus safer to administer in the acute setting. Local guidelines 2 quote this commonly held notion of the side-effects of buprenorphine whilst referring to a small pharmacokinetic study and a retrospective review addressing chronic pain. 4, 39 These data were largely drawn from administration in young, healthy patients, who differ substantially from those for whom it is often prescribed. On the other hand, small case series have been recently published citing the effect of buprenorphine on respiratory drive and associated adverse outcomes. 5, 40 Unsurprisingly, local guidelines have been judged by many clinicians to hold greater sway than a small number of case studies. The effect of buprenorphine on respiratory rate has been published in many early studies. 3, 8, 14, 15, 25 It typically leads to preserved tidal volumes with a slow decrease in ventilatory rates over a few hours. As such, it is important to be aware of the possibility of delayed ventilatory depression in the adult and paediatric population. This review provides level-one evidence that there is no significant difference in the incidence of respiratory depression with morphine compared with buprenorphine. Whilst a theoretical ceiling effect may exist with respect to respiratory depression, is would seem that in clinical application there is still a profound effect on the respiratory drive that can lead to significant adverse outcomes. This has significant clinical implications when considering the use of this agent for the management of acute pain, particularly in patients with reduced respiratory reserve. Patients who experience respiratory depression after administration of buprenorphine will likely have risk factors that warrant escalation of care to high dependency or intensive care units. In addition, the unique pharmacodynamics of buprenorphine as a semisynthetic opioid with significant affinity for mu receptors leads to further complexities associated with naloxone reversal. Case reports of buprenorphine-related respiratory depression show a resistance to attempts at reversal with naloxone thought secondary to the drugs high affinity and slow dissociation from opioid receptors. 5 Naloxone also displays faster elimination kinetics than buprenorphine and therefore recurrence of respiratory depression is likely after single naloxone doses. 39 Regarding sedation, few studies detailed adequate, reproducible scales for assessing sedation with most commenting on the incidence of 'drowsiness' or 'sleepiness'. Notwithstanding these limitations, there was no significant difference in the incidence of sedation between the two agents. Maunuksela and colleagues, 26 who assessed a paediatric population, acknowledged the limitations in assessing sedation in children after operation; the higher incidence of sedation in the buprenorphine arm may have been represented analgesia in children who simply fell asleep. The incidence of pruritus is significantly higher with the use of morphine. This is not a new finding, but it is another reason why buprenorphine is a suitable alternative for those who develop this often highly distressing symptom. After analysis of other side effects, there is no significant difference in the incidence nausea, vomiting, dizziness, or hypotension.
Limitations
Notably, we chose to include a wide range of studies utilizing heterogeneous acute pain settings for this review. Some have criticized the utility of analyses combining heterogeneous results. 41 Whilst we recognize the issues with grouping such heterogenous sample populations, in this case we chose to combine results for a wide range of 'pain-models' given that guidelines on the use of opioid prescription are largely independent of the type of acute pain, and many clinicians' approaches (including our own) are in fact relatively homogenous and primarily influenced by patient factors which would be controlled for in these RCTs. We recognize that some practitioners will feel that an individual RCT may be more relevant to their practise, and this is to be encouraged. We simply encourage readers to consider the findings of this larger analysis when prescribing to at-risk populations. This analysis also used measures of respiratory depression as a surrogate outcome for other, more serious complications of narcotization. Difficulties which surround the use of surrogate clinical outcome measures are recognized by this group, and have been known and discussed for a long time. 42 With an increasing availability of large datasets and automatically collated data, perhaps a large RCT analysing outcomes such as need for ventilator support, ICU admission, or mortality may be possible. Until then, we felt this was a reasonable and validated surrogate measure to inform clinical decision-making with its own clinical implications in those with reduced reserve. Interestingly, only four studies declared support from pharmaceutical companies, in the form of medication supply. 24e26,28 This minimizes the external bias that may have influenced the results of this study.
Conclusion
In conclusion, this meta-analysis suggests that a heightened level of awareness is required when administered buprenorphine for the treatment of acute pain because of an equal incidence of side-effects when compared with morphine. Whilst a theoretical ceiling effect may exist with respect to buprenorphine and respiratory depression, in a clinical setting, it can still cause significant adverse effects on respiratory function. Buprenorphine was an equally effective analgesic agent and remains a useful alternative opioid because of its ease of administration and duration of action, and a reduced incidence of pruritus.
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